Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection
暂无分享,去创建一个
U. Spengler | J. Trebicka | J. Rockstroh | C. Boesecke | B. Clotet | J. Wasmuth | J. Llibre | S. Schlabe | C. Schwarze‐Zander | J. Malin | M. Vasylyev | J. Llibre | T. Jou | Ulrich Spengler | B. Clotet | J. Wasmuth | J. Rockstroh
[1] S. Kedia,et al. Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography. , 2018, Journal of clinical and experimental hepatology.
[2] W. Alexander,et al. European Association for the Study of the Liver , 1968 .
[3] J. Rockstroh,et al. Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients , 2018, PloS one.
[4] G. Robbins,et al. Direct-Acting Antiviral Therapy for Chronic HCV Infection Results in Liver Stiffness Regression Over 12 Months Post-treatment , 2018, Digestive Diseases and Sciences.
[5] H. Toyoda,et al. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct‐acting antiviral therapy and achieved sustained virological response , 2017, Journal of gastroenterology and hepatology.
[6] M. Johnson,et al. Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals , 2017, Scientific Reports.
[7] B. Seifert,et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis‐4 score and aspartate aminotransferase‐platelet ratio index , 2017, Liver international : official journal of the International Association for the Study of the Liver.
[8] M. Trauner,et al. Interferon‐free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease , 2017, Alimentary pharmacology & therapeutics.
[9] A. Crissien-Martinez,et al. Degree of liver fibrosis regression predicted by transient elastography after cure of chronic hepatitis C with direct acting antivirals is overestimated but confirmed by liver biopsy , 2017 .
[10] J. Pawlotsky,et al. EASL Recommendations on Treatment of Hepatitis C 2016. , 2017, Journal of hepatology.
[11] M. Friedrich-Rust,et al. Regression of fibrosis and portal hypertension in HCV‐associated cirrhosis and sustained virologic response after interferon‐free antiviral therapy , 2016, Journal of viral hepatitis.
[12] P. Schwabl,et al. Advances in the management of HIV/HCV coinfection , 2016, Hepatology International.
[13] J. Rockstroh,et al. Liver Fibrosis in HIV Patients Receiving a Modern cART , 2015, Medicine.
[14] Anrs Co Hepavih Cohort. Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patients , 2015, AIDS.
[15] Fabio Nascimbeni,et al. Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[16] C. Strassburg,et al. Circulating MicroRNAs as a marker for liver injury in human immunodeficiency virus patients , 2015, Hepatology.
[17] E. Tapper,et al. FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[18] M. Karsdal,et al. Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers , 2014, AIDS.
[19] Stefan Zeuzem,et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.
[20] Sanjeev Arora,et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. , 2014, The New England journal of medicine.
[21] A. Lok,et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. , 2014, The New England journal of medicine.
[22] V. de Lédinghen,et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography , 2013, Hepatology.
[23] N. Afdhal. Fibroscan (transient elastography) for the measurement of liver fibrosis. , 2012, Gastroenterology & hepatology.
[24] M. Ziol,et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C , 2012, Journal of viral hepatitis.
[25] V. Soriano,et al. Risk factors for advanced liver fibrosis in HIV‐infected individuals: role of antiretroviral drugs and insulin resistance , 2011, Journal of viral hepatitis.
[26] M. Mohraz,et al. Hepatitis-C and hepatitis-B co-infections in patients with human immunodeficiency virus in Tehran, Iran. , 2011, Acta medica Iranica.
[27] Richard D Moore,et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] F. Oberti,et al. Reproducibility of liver stiffness measurement by ultrasonographic elastometry. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[29] O. Pybus,et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. , 2008, The Journal of infectious diseases.
[30] Eva Herrmann,et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. , 2008, Gastroenterology.
[31] X. Forns,et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[32] V. de Lédinghen,et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study , 2005, Gut.
[33] J. Rodríguez-Orengo,et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. , 2006, Journal of hepatology.
[34] A. Mocroft,et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. , 2005, The Journal of infectious diseases.
[35] V. de Lédinghen,et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.
[36] J. Rockstroh,et al. HIV and hepatitis C virus co-infection. , 2004, The Lancet. Infectious diseases.
[37] G. Sirera,et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co‐infected patients , 2003, Journal of viral hepatitis.
[38] F. Callea,et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. , 2001, The Journal of infectious diseases.
[39] T. Sauerbruch,et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. , 1996, The American journal of gastroenterology.
[40] J. Goedert,et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. , 1993, Journal of acquired immune deficiency syndromes.